NICE has rejected imatinib (Glivec) as an adjuvant treatment for people who have had a gastrointestinal stromal tumour removed and who are at risk of the cancer recurring.
NICE said there was not currently enough evidence about the clinical effectiveness of imatinib, such as whether it extends life expectancy, to recommend it for the NHS.
Introducing Nursing Times Learning
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Click on the topics below to get started: